Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Medroxyprogesterone in Treating Women With Breast Cancer
This study is ongoing, but not recruiting participants.
Study NCT00002920 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Endometrial Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Endometrial Neoplasms
More general conditions related to this trial
Breast Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms
Neoplasms by Site
Skin Diseases
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
medroxyprogesterone
tamoxifen citrate
adjuvant therapy
Additional drug interventions recognized in this trial
Medroxyprogesterone 17-Acetate
Tamoxifen
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Therapeutic Uses
Sponsors listed in this trial
Southwest Oncology Group
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Back to top of Main Content
